Mdxhealth S.A. (MDXH)
NASDAQ:MDXH
Want to see MDXH full AI Analyst Report?
MDXH Stock Chart & Stats
$2.31
-$0.10(-4.55%)
At close: 4:00 PM EST
$2.31
-$0.10(-4.55%)
Day’s Range― - ―
52-Week Range$0.51 - $5.33
Previous CloseN/A
Volume27.23K
Average Volume (3M)937.73K
Market Cap
$32.93M
Enterprise Value$105.11M
Total Cash (Recent Filing)$29.03M
Total Debt (Recent Filing)$95.11M
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Aug 13, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding51,364,520
10 Day Avg. Volume897,516
30 Day Avg. Volume937,726
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market Cap3.19
Enterprise Value/Revenue1.29
Enterprise Value/Gross Profit2.24
Enterprise Value/Ebitda-17.17
Forecast
1Y Price Target
$3.38Price Target Upside46.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.62
Revenue Forecast (FY)$116.22M
Bulls Say, Bears Say
Bulls Say
Revenue Scaling & Unit EconomicsMaterial multi-year revenue expansion with sustained ~60% gross margins indicates strong unit economics for MDxHealth’s diagnostic tests. Durable volume-driven revenue growth plus healthy product-level margins support long-term operating leverage as lab capacity and commercial reach scale.
Commercial Integration SuccessSuccessful integration and customer migration after the ExoDx acquisition demonstrates execution on consolidating sales efforts and reducing overlap. This structurally strengthens go-to-market efficiency, improves rep productivity, and creates durable revenue synergies from a unified prostate cancer portfolio.
AI & Clinical InnovationA strategic AI program and inclusion of AI endpoints in the Oxford PROTECT trial create sustainable product differentiation. Building an AI data platform and stronger prognostic evidence can embed MDxHealth tests deeper in clinical workflows and support long-term payer and guideline adoption.
Bears Say
Elevated Leverage & Negative EquityA sharp increase in debt and negative shareholders’ equity materially weakens financial flexibility. Over a multi-month horizon this elevates refinancing, covenant, and dilution risk, constraining investments in commercialization, R&D, and possible M&A unless cash generation materially improves.
Persistent Cash BurnOngoing negative operating and free cash flow means the business remains dependent on external capital to fund growth and integration costs. Until sustainable positive cash generation is achieved, liquidity management will limit strategic optionality and increase the cost of capital over the medium term.
Payer/Regulatory & Strategic Retreat RiskA potential $10.4M Medicare recoupment and the forced exit of Resolve reflect structural payer and reimbursement vulnerabilities. The loss of a business line reduces diversification and shows that adverse reimbursement decisions can materially alter revenue mix and require costly restructuring over months.
MDxHealth News
MDXH FAQ
What was Mdxhealth S.A.’s price range in the past 12 months?
Mdxhealth S.A. lowest stock price was $0.51 and its highest was $5.33 in the past 12 months.
What is Mdxhealth S.A.’s market cap?
Mdxhealth S.A.’s market cap is $32.93M.
When is Mdxhealth S.A.’s upcoming earnings report date?
Mdxhealth S.A.’s upcoming earnings report date is Aug 13, 2026 which is in 71 days.
How were Mdxhealth S.A.’s earnings last quarter?
Mdxhealth S.A. released its earnings results on May 13, 2026. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.145 by -$0.045.
Is Mdxhealth S.A. overvalued?
According to Wall Street analysts Mdxhealth S.A.’s price is currently Undervalued.
Does Mdxhealth S.A. pay dividends?
Mdxhealth S.A. does not currently pay dividends.
What is Mdxhealth S.A.’s EPS estimate?
Mdxhealth S.A.’s EPS estimate is -0.19.
How many shares outstanding does Mdxhealth S.A. have?
Mdxhealth S.A. has 51,364,520 shares outstanding.
What happened to Mdxhealth S.A.’s price movement after its last earnings report?
Mdxhealth S.A. reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.145. Following the earnings report the stock price went down -49.538%.
Which hedge fund is a major shareholder of Mdxhealth S.A.?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MDxHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.38 (46.10% Upside)
$3.38 (46.10% Upside)
Blogger Sentiment
Bullish
MDXH Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 24.4%
Last 30 Days ▲ 24.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.86%
12-Months-Change
Fundamentals
Return on Equity
402.97%
Trailing 12-Months
Asset Growth
-8.01%
Trailing 12-Months
Company Description
Mdxhealth S.A.
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
MDXH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presents a mixed but cautiously positive outlook: operationally the company is refocusing on its high-growth prostate cancer franchise with clear commercial integration wins (ExoDx transition, sales cross-training), AI initiatives, and a raised 2026 revenue target implying 20–26% growth. However, material near-term headwinds exist — most notably the strategic exit of the Resolve UTI business, a Novitas recoupment notice up to $10.4M, pro forma margin compression, and a wider operating loss driven by the ExoDx acquisition and integration — all of which create execution and liquidity considerations in the short term. Overall, management frames the Resolve exit as a proactive, value-accretive repositioning to prioritize scalable core growth while defending against payer recoupment risk.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$3.38
▲(46.10% Upside)
Technical Analysis
Ownership Overview
―
Insiders
1.45% Mutual Funds
20.13% Other Institutional Investors
78.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---